Showing results (281-290 of 483) with videos related to

Sort By:
Pageof 49
Leukemia & Lymphoma|April 26, 2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myelomaPaula Rodriguez-Otero, Dieter Ayers, Shannon Cope, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|June 22, 2026
Dorsal spinal instrumentation in multiple myeloma: postoperative acute kidney injury is associated with mortality, morbidity, and deterioration of bone and muscle statusJulian Kylies, Leon-Gordian Leonhardt, Elias Brauneck, et al.
Onkologie|April 27, 2007
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II studyJörg Thomas Hartmann, Jan Peter Pintoffl, Salah-Eddin Al-Batran, et al.
In Vivo (Athens, Greece)|April 24, 2012
In vitro effects of doxycycline on inflammatory cytokines and gelatinases in chronic rhinosinusitisJ Ulrich Sommer, Johannes D Schultz, Judith Grossbaier, et al.
Scientific Reports|January 12, 2020
Label-free impedance flow cytometry for nanotoxicity screeningMelanie Ostermann, Alexander Sauter, Ying Xue, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2005
Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanomaChristian Müller-Horvat, Peter Radny, Thomas K Eigentler, et al.
Oncotargets and Therapy|September 3, 2025
The Role of CELMoD Agents in Multiple MyelomaNiels W C J van de Donk, Nizar J Bahlis, Charlotte Pawlyn, et al.
Blood Cancer Journal|February 7, 2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug developmentPralay Mukhopadhyay, Hesham A Abdullah, Joanna B Opalinska, et al.
Blood Cancer Journal|March 11, 2020
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysisMeletios A Dimopoulos, Ruben Niesvizky, Katja Weisel, et al.
Oral Oncology|January 22, 2008
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinomaHerbert Riechelmann, Alexander Sauter, Wolfram Golze, et al.
Pageof 49